Stability Data Reporting Section In FDA Draft Report Will Be Amended
This article was originally published in The Tan Sheet
Executive Summary
FDA will change the stability data reporting section of its June 1998 draft stability guidance to address comments to the agency following the draft's release, Center for Drug Evaluation & Research Stability Coordinating Committee Chairman Robert Seevers, PhD, said at an industry/FDA "Stability Testing and Control" meeting in East Rutherford, N.J. June 28.
You may also be interested in...
Stability testing and control
Workshops addressing avoidance of stability issues in the development of drug products, sponsored by CHPA, FDA, USP and other bodies, will be held in New Jersey June 28, Puerto Rico July 19, Missouri Aug. 2 and California Aug. 16. Objectives for the workshops include a review of the FDA draft guidance on stability released in June 1998, methods for establishing expiration dates and ensuring methods are stability indicating
Labeled Storage Statements On OTCs Opposed By NDMA
Labeled storage statements should not be applied to products marketed to consumers, and this exemption should be stated specifically in FDA's revised guidance for industry on drug stability testing, the Nonprescription Drug Manufacturers Association urges in Dec. 7 comments to the agency.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC